6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Cross-Tolerance in Substance Use
Cross-tolerance occurs when the use of one substance reduces sensitivity to another, often due to overlapping mechanisms of action. For example, tolerance to alcohol may result in reduced responsiveness to benzodiazepines, as both affect the GABAergic system. This phenomenon complicates treatment and increases the risk of overdose when individuals switch or combine substances to achieve the desired effect. Cross-tolerance is a significant challenge in managing polysubstance use disorders, as it may necessitate higher doses of medications for effective treatment, increasing potential side effects. Treatment strategies include careful assessment of cross-tolerance patterns, gradual tapering protocols, and alternative medications that bypass tolerance mechanisms. Recognizing cross-tolerance is critical in designing safer and more effective addiction management plans.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States